Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy

NCT02386553 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT02386553
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02386553 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
Lead sponsor
Biogen
Phase
Phase 2
Overall status
Completed
Start date
May 18, 2015
Completion date
December 17, 2024
Enrollment
25 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

spinal muscular atrophy